Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) protein is a major surface glycoprotein of the influenza B virus (B Victoria lineage), responsible for binding to host cell receptors and facilitating viral entry. It is a key target for neutralizing antibodies and a crucial component in vaccine formulations. The Victoria lineage is antigenically distinct from the Yamagata lineage, necessitating their co-inclusion in quadrivalent vaccines.
Neutralization of viral entry by antibody binding to hemagglutinin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin Protein of Influenza B Virus (B Victoria Lineage).